ImageneBio (IMA) CEO Kristin Yarema Receives Equity Awards

What Happened
Kristin Yarema, CEO of ImageneBio, was granted equity on August 14, 2026: 254,800 restricted stock units (RSUs) and two option awards totaling 387,200 underlying shares (137,200 and 250,000). All items were reported at $0 purchase price because these are compensation grants (no cash changed hands). RSUs represent the right to receive one share per RSU upon settlement; the options are standard time‑based grants.

Key Details

• Transaction date: August 14, 2026; Form 4 filed August 17, 2026 (filing within required business-day window).
• Grants reported as: 254,800 RSUs (F1), 137,200 options (F2), and 250,000 options (F3). Total units/underlying shares = 642,000.
• Reported dollar price per share: $0.00 (compensation grant).
• Shares owned after transaction: not specified in the provided filing summary.
• Vesting/settlement notes from the filing:
  • F1 (RSUs): 25% vest and settle into common stock on April 14, 2027; remaining RSUs vest in 12 equal quarterly installments thereafter, subject to continued service.
  • F2 (first option grant): 4‑year schedule with 25% vesting on April 14, 2027, then the remainder in 36 equal monthly installments, subject to continued service.
  • F3 (second option grant): vests over four years in 48 equal monthly installments beginning May 14, 2026, subject to continued service.
• Transaction code: A (Award/Grant).

Context
These grants are compensation awards and not open‑market purchases or sales; they do not immediately indicate buying or selling intent. RSUs convert to shares upon vesting/settlement; options require vesting (and exercise) before becoming shares. Vesting is time‑based and contingent on Yarema’s continued service, per the disclosed schedules.